US FDA review boosts odds for Wockhardt’s NCE success story: Vishal Manchanda

Wockhardt moved a step closer to a major US launch after the US FDA accepted its New Drug Application (NDA) for review, raising investor optimism and pushing the stock up nearly 18% on Monday. According to Vishal Manchanda, Equity Research Analyst – Pharma at Systematix Group, the drug—Zaynich—has not yet been approved, but the review acceptance significantly improves its probability of success.

Manchanda clarified that the FDA’s acceptance triggers a priority review cycle, which typically lasts around six months. “We are still looking at an approval timeline in early FY27,” he said. However, the company’s planned mid-2026 launch guidance remains on track, given the accelerated review status.

Drug generates strong buzz

The drug has generated strong buzz in the market due to its promising clinical data and its importance in India’s pursuit of developing Novel Chemical Entities (NCEs). “This is a milestone for Wockhardt and for the Indian pharma innovation ecosystem,” Manchanda noted, even though he refrained from commenting on valuations.


Wockhardt is also developing other pipeline drugs, but according to Manchanda, those assets are currently geared more towards India-driven opportunities rather than the US market. For now, investor focus remains on Zaynich and its fast-advancing regulatory journey.